Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (621) Arrow Down
Filter Results: (621) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (621)
    • People  (2)
    • News  (57)
    • Research  (447)
    • Events  (2)
    • Multimedia  (9)
  • Faculty Publications  (391)

Show Results For

  • All HBS Web  (621)
    • People  (2)
    • News  (57)
    • Research  (447)
    • Events  (2)
    • Multimedia  (9)
  • Faculty Publications  (391)
← Page 20 of 621 Results →
  • 07 Feb 2005
  • Research & Ideas

How “Career Imprinting” Shapes Leaders

Abbott's career imprint could be called a "functional career imprint." Baxter generated a disproportionate number of leaders in the biotechnology industry. During the early 1980s, when the biotech industry was just heating up... View Details
Keywords: by Mallory Stark
  • 01 Mar 2005
  • News

A Primer on Patents

fifteen years ago, as a doctoral candidate in Harvard’s Economics Department, Lerner was collecting data on the role of VC funding in the biotechnology industry. Before long, he also became intrigued by the concept of intellectual... View Details
Keywords: James E. Aisner; Colleges, Universities, and Professional Schools; Educational Services
  • 01 Mar 2003
  • News

Naina Lal Kidwai

to the global automobile industry. Biotechnology and pharmaceutical firms are emerging as international players. There are also opportunities in infrastructure investment, such as telecom, ports, roads, and airports. Please comment on... View Details
Keywords: Garry Emmons; Funds, Trusts, and Other Financial Vehicles; Finance
  • November 2023 (Revised April 2024)
  • Case

BiomX: Bringing Phage Back to the Stage

By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)
  • September 2023 (Revised April 2024)
  • Case

Atomwise: Strategic Opportunities in AI for Pharma

By: Satish Tadikonda
Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details
Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Tadikonda, Satish. "Atomwise: Strategic Opportunities in AI for Pharma." Harvard Business School Case 824-043, September 2023. (Revised April 2024.)
  • January 2014
  • Supplement

Amgen Inc.: Pursuing Innovation and Imitation? (B)

By: Ian Mackenzie
The (B) case reveals that Sharer decided that Amgen should enter the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The... View Details
Keywords: Corporate Strategy; Biotechnology Industry; Biotechnology Industry; United States
Citation
Purchase
Related
Mackenzie, Ian. "Amgen Inc.: Pursuing Innovation and Imitation? (B)." Harvard Business School Supplement 714-426, January 2014.
  • June 2012
  • Case

GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships

By: Arthur A. Daemmrich and Ian McKown Cornell
Three years into a major public-private partnership between GlaxoSmithKline and Fiocuz, Brazil's principal health institute, the company assesses technology transfer and joint research under the agreement. GSK was selling its Synflorix vaccine (against pediatric... View Details
Keywords: Public-Private Partnerships; Business and Government Relations; Foreign Direct Investment; Health Care and Treatment; Globalized Firms and Management; Biotechnology Industry; Biotechnology Industry; Brazil
Citation
Educators
Purchase
Related
Daemmrich, Arthur A., and Ian McKown Cornell. "GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships." Harvard Business School Case 712-049, June 2012.
  • April 2011
  • Supplement

Roche's Acquisition of Genentech (CW)

By: Bo Becker
Spreadsheet for case 210040. View Details
Keywords: Biotechnology Industry; Biotechnology Industry
Citation
Purchase
Related
Becker, Bo. "Roche's Acquisition of Genentech (CW)." Harvard Business School Spreadsheet Supplement 211-706, April 2011.
  • March 2011 (Revised June 2012)
  • Case

Office of Technology Transfer - Shanghai Institutes for Biological Sciences

By: Willy Shih, Sen Chai, Kamen Bliznashki and Courtney Hyland
Gordon Zong is trying to teach Chinese universities and research institutes how to do effective technology transfer and IP licensing, but he is trying to do it in an environment with weak property rights and an underdeveloped support infrastructure. As the managing... View Details
Keywords: Multinational Firms and Management; Patents; Knowledge Management; Law Enforcement; Business and Government Relations; Research and Development; Biotechnology Industry; Biotechnology Industry; China
Citation
Educators
Purchase
Related
Shih, Willy, Sen Chai, Kamen Bliznashki, and Courtney Hyland. "Office of Technology Transfer - Shanghai Institutes for Biological Sciences." Harvard Business School Case 611-057, March 2011. (Revised June 2012.)
  • 24 Jun 2008
  • Conference Presentation

The effect of heterogeneous institutional actors on entrepreneurial activity and resource attainment in the U.S. biodiesel industry

By: Shon R. Hiatt
Keywords: Entrepreneurship; Biotechnology Industry; Biotechnology Industry; United States
Citation
Related
Hiatt, Shon R. "The effect of heterogeneous institutional actors on entrepreneurial activity and resource attainment in the U.S. biodiesel industry." Paper presented at the Cornell-McGill Conference on Institutions and Entrepreneurship, Montreal, Quebec, June 24, 2008.
  • 2010
  • Working Paper

Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe

By: Christopher C. Liu and Toby E. Stuart
In innovative industries, private-sector companies increasingly are participants in open communities of science and technology. To participate in the system of exchange in such communities, firms often publicly disclose what would otherwise remain private discoveries.... View Details
Keywords: For-Profit Firms; Higher Education; Information Publishing; Innovation and Invention; Science-Based Business; Social and Collaborative Networks; Boundaries; Biotechnology Industry; Biotechnology Industry
Citation
Read Now
Related
Liu, Christopher C., and Toby E. Stuart. "Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe." Harvard Business School Working Paper, No. 11-012, August 2010.
  • November 2007
  • Class Lecture

The Baby Business (FSS)

By: Debora L. Spar
In vitro fertilization and genetic screening are possible with the advent of biotechnology. International adoptions, surrogacy, and other approaches to family planning are on the rise. But few rules govern these measures, medical costs can be prohibitive, and... View Details
Keywords: Governing Rules, Regulations, and Reforms; Policy; Demand and Consumers; Business and Government Relations; Business and Stakeholder Relations; Genetics; Societal Protocols; Commercialization; Biotechnology Industry; Biotechnology Industry
Citation
Find at Harvard
Related
Spar, Debora L. "The Baby Business (FSS)." Harvard Business School Class Lecture 708-701, November 2007.
  • November 2007
  • Case

Antegren: A Beacon of Hope

By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann
The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion... View Details
Keywords: Demand and Consumers; Leadership; Ethics; Corporate Social Responsibility and Impact; Decision Choices and Conditions; Crisis Management; Health Testing and Trials; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Margolis, Joshua D., Thomas J. DeLong, and Terence Heymann. "Antegren: A Beacon of Hope." Harvard Business School Case 408-025, November 2007.
  • June 2004 (Revised May 2005)
  • Case

Judah Folkman and the War on Cancer

Judah Folkman, professor in the Division of Vascular Biology at Children's Hospital in Boston, is considering how best to advance the research in his lab in an era where biomedical research has gotten more interdisciplinary and collaborative. Specifically, Folkman has... View Details
Keywords: Conflict of Interests; Leadership; Research; Personal Development and Career; Health Care and Treatment; Collaborative Innovation and Invention; Biotechnology Industry; Biotechnology Industry; Boston
Citation
Find at Harvard
Related
West, Jonathan, Ambuj Sagar, and Mona Ashiya. "Judah Folkman and the War on Cancer." Harvard Business School Case 604-091, June 2004. (Revised May 2005.)
  • September 1995
  • Case

Ares-Serono

By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details
Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Biotechnology Industry; Biotechnology Industry; Switzerland; Europe
Citation
Find at Harvard
Related
Yoshino, Michael Y., Jean-Pierre Jeannet, and Carin-Isabel Knoop. "Ares-Serono." Harvard Business School Case 396-035, September 1995.
  • 12 Sep 2006
  • First Look

First Look: September 12, 2006

alliance contracts, all of which concern early-stage research at small, biotechnology R&D companies. Staged investment is ubiquitous, but solutions to agency problems vary. The cycle of equity participation in alliances resembles what... View Details
Keywords: Sean Silverthorne
  • September 2008 (Revised July 2012)
  • Case

Khosla Ventures: Biofuels Strategy

By: Joseph B. Lassiter III, William A. Sahlman and Alison Berkley Wagonfeld
By 2008, a number of the firm's early cleantech investments were showing promise, and the companies were starting to need significantly more money to create the massive scale required in the energy sector. As Khosla thought about the hundreds of millions of dollars... View Details
Keywords: Entrepreneurial Marketing; Entrepreneurial Finance; New Product Development; Partnerships; Entrepreneurial Management; Venture Capital; Strategy; Partners and Partnerships; Renewable Energy; Entrepreneurship; Investment Funds; Environmental Sustainability; Product Development; Biotechnology Industry; Biotechnology Industry
Citation
Educators
Purchase
Related
Lassiter, Joseph B., III, William A. Sahlman, and Alison Berkley Wagonfeld. "Khosla Ventures: Biofuels Strategy." Harvard Business School Case 809-004, September 2008. (Revised July 2012.)
  • 01 Nov 2024
  • In Practice

Layoffs Surging in a Strong Economy? Advice for Navigating Uncertain Times

decision about entrepreneurship Starting your own company after a layoff is a significant decision. While it may seem like an opportune time, research suggests there are some important considerations. “Entrepreneurs coming from high-tech sectors such as View Details
Keywords: by Rachel Layne; Technology; Information Technology
  • 06 Oct 2020
  • Blog Post

2+2 Where Are They Now Spotlight: Curtis Wu (MBA 2018)

Can you describe your role?I currently work at Amgen Inc at their global HQ in Southern California. Amgen is the largest independent biotechnology company in the world by revenue and our top medicines include autoimmune drug Enbrel, white... View Details
  • 01 Aug 2002
  • News

For Alumni Only: Breakthrough Insights Program Debuts

case on the biotechnology firm Biogen, where a seemingly innocuous decision to license databases of new proteins discovered through genomic research wound up completely transforming the company's product-development process. As Vietor led... View Details
Keywords: Laura Singleton
  • ←
  • 20
  • 21
  • …
  • 31
  • 32
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.